英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
sonorophone查看　sonorophone　在百度字典中的解释百度英翻中〔查看〕
sonorophone查看　sonorophone　在Google字典中的解释Google英翻中〔查看〕
sonorophone查看　sonorophone　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Meeting Abstract: 2025 ASCO Annual Meeting I - ASCO Publications
    TROPION-Lung14 is evaluating the efficacy and safety of osimertinib ± Dato-DXd as 1L therapy in patients with EGFR-mutated LA M NSCLC Methods: TROPION-Lung14 (NCT06350097) is an ongoing phase 3, open-label, multicentre, randomized study
  • Professor Xue Yang: ADC Research Updates from the 2025 ELCC Conference
    The study focused on patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who experienced disease progression after first-line osimertinib In the 6 mg kg Dato-DXd cohort, the objective response rate (ORR) reached 36%, with a median progression-free survival (PFS) of 11 7 months and a median duration of response (DoR) of 20 5
  • Phase III, Open-label Study of First-line Osimertinib With or Without . . .
    The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Datopotamab Deruxtecan (i v infusion) compared with osimertinib (tablet) monotherapy as a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and or L858R) NSCLC
  • Overall Survival in EGFR-Mutant Advanced NSCLC Treated With . . . - PubMed
    The third-generation tyrosine kinase inhibitor, osimertinib, is approved for first-line EGFRm NSCLC We used longitudinal U S medical oncology databases to evaluate real-world overall survival (rwOS) and prognostic risk factor groups in advanced EGFRm NSCLC treated with first-line osimertinib
  • European Lung Cancer Congress 2025 | OncologyPRO
    European Lung Cancer Congress 2025 Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived? Osimertinib monotherapy remains our current standard of care
  • Opinion: Chemo-Free Regimens Join Crowded Field of Potential Therapies . . .
    Results from all 3 trials were recently presented at the European Lung Cancer Congress (ELCC) 2025 The phase 2 trial (NCT03944772) included patients with EGFR -mutant, advanced NSCLC that had
  • Several Trials Show Clinical Activity With Osimertinib in Advanced
    Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lung Cancer Congress (ELCC) 2025
  • FDA Approves Osimertinib for Locally Advanced, Unresectable (Stage III . . .
    On September 25, 2024, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose
  • Neoadjuvant Osimertinib: A Step Ahead or Just a Step?
    Leading this list is osimertinib, which is a selective third-generation EGFR TKI, used routinely for the treatment of patients with lung adenocarcinoma whose tumor harbors the activating EGFR exon 19 deletion or exon 21 L858R point mutation
  • Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell . . .
    Adjuvant osimertinib is the standard of care for patients with resected epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) Neoadjuvant treatment could improve surgical and long-term outcomes
  • Osimertinib - UPMC Health Library
    tell your doctor and pharmacist if you are allergic to osimertinib, any other medications, or any of the ingredients in osimertinib tablets Ask your pharmacist for a list of the ingredients tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking
  • Frontline Options for Metastatic EGFR-Mutated NSCLC: Taking Advantage . . .
    The current frontline options include osimertinib monotherapy, osimertinib plus chemotherapy, and amivantamab plus lazertinib, with the combination approaches providing better progression-free survival (PFS) but worse toxicity and treatment burden
  • HSR25-159: Real-World Effectiveness of First-Line Osimertinib for . . .
    We examined outcomes in a cohort of pts with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC who were eligible for Medicare and treated with first-line (1L) osimertinib (osi), a third-generation, irreversible, CNS-active EGFR-tyrosine kinase inhibitor that is currently the preferred 1L treatment (tx) for EGFRm (Ex19Del L858R
  • Advancing the Needle on the Management of Resectable EGFR-Positive . . .
    Adjuvant osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), reported improved disease-free survival (DFS) and overall survival (OS) over placebo for patients with stage IB to IIIA NSCLC harboring classical EGFR mutations (exon 19 deletion or L858R) in the landmark ADAURA trial 1 Although this was a practice-changing trial
  • Optimizing Osimertinib for NSCLC: Targeting Resistance and . . . - PubMed
    We explore key strategies that pair osimertinib with radiotherapy, anti-angiogenic agents, immune checkpoint inhibitors, and other molecularly targeted drugs, and we discuss the biological rationale, preclinical evidence, and clinical trial data supporting these approaches





中文字典-英文字典  2005-2009